BioStock

Prenumeration

Cereno Scientific: BioStock: Cereno's CEO - "CS014 adds potential for cardiovascular disease patients"

2024-06-20 07:46:00

Cereno Scientific is a biotech company developing treatments for the number one killer in the world - cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 - a novel epigenetic HDAC inhibitor. Cereno's CEO Sten R Sörensen stopped by the BioStock Studio to share more details about the news.

Read the interview at biostock.se:

Cereno's CEO: "CS014 adds potential for cardiovascular disease patients" - BioStock (https://www.biostock.se/en/2024/06/cerenos-ceo-cs014-adds-potential-for-cardiovascular-disease-patients/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden